We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
An esophagus-sparing technique to limit radiation esophagitis in locally advanced non-small cell lung cancer treated by simultaneous integrated boost intensity-modulated radiotherapy and concurrent chemotherapy.
- Authors
Ma, Li; Qiu, Bo; Li, QiWen; Chen, Li; Wang, Bin; Hu, YongHong; Liu, MengZhong; Zhang, Li; Huang, Yan; Deng, XiaoWu; Xia, YunFei; Lin, MaoSheng; Liu, Hui
- Abstract
<bold>Background: </bold>To investigate the incidence of radiation esophagitis (RE) and tumor local control using esophagus sparing technique in locally advanced non-small cell lung cancer (LANSCLC) treated by simultaneous integrated boost intensity-modulated radiation therapy (SIB-IMRT) and concurrent chemotherapy.<bold>Methods: </bold>Eighty-seven patients with stage IIIA/B NSCLC who received definitive SIB-IMRT and concurrent chemotherapy had been divided into two groups: 1.with esophagus sparing technique; 2.without esophagus sparing technique. Chi-square test was performed to compare sex, clinical stage, histology, concurrent chemotherapy, RE and nutrition status between two groups. T-test was used to compare the dosimetric parameters. Overall survival (OS) and loco-regional failure free survival (LRFS) were calculated by the Kaplan-Meier method and compared by a log-rank test.<bold>Results: </bold>There were 44 patients in the esophagus sparing group and 43 in the non-sparing group. The incidence of severe RE (Grade 3) was significantly lower in patients with esophagus sparing technique (p = 0.002). Patients in esophagus sparing group had better nutrition status (p = 0.045). With a median follow-up of 18 months (range 1-51 months), the 1-year, 2-year and 3-year OS of all the patients was 86.6, 65.4 and 43.7%. The 1-year, 2-year LRFS was 78.4, 65.9%. OS time (p = 0.301) and LRFS (p = 0.871) was comparable between two groups.<bold>Conclusions: </bold>Esophagus-sparing technique is an effective and essential method to limit RE in LANSCLC treated by SIB-IMRT and concurrent chemotherapy without compromising local control.
- Subjects
EOSINOPHILIC esophagitis; NON-small-cell lung carcinoma; CHEMORADIOTHERAPY; CANCER treatment; CANCER chemotherapy
- Publication
Radiation Oncology, 2018, Vol 13, Issue 1, pN.PAG
- ISSN
1748-717X
- Publication type
journal article
- DOI
10.1186/s13014-018-1073-3